Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 9.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 516,491 shares of the company’s stock after purchasing an additional 43,146 shares during the quarter. Northern Trust Corp owned 0.65% of Immunome worth $5,485,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome during the 4th quarter worth approximately $75,000. AlphaQuest LLC grew its stake in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares during the period. Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter worth approximately $95,000. Finally, Stoneridge Investment Partners LLC acquired a new stake in shares of Immunome during the 4th quarter worth approximately $123,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Up 6.9%

Shares of NASDAQ:IMNM opened at $8.56 on Wednesday. The business has a 50-day moving average price of $7.62 and a 200 day moving average price of $9.76. The company has a market capitalization of $744.82 million, a price-to-earnings ratio of -1.06 and a beta of 2.00. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. As a group, equities research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Clay B. Siegall purchased 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. The trade was a 20.47% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $8.21 per share, with a total value of $57,470.00. Following the acquisition, the director now directly owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 156,400 shares of company stock worth $1,160,495 in the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lake Street Capital assumed coverage on Immunome in a research report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price on the stock. Wedbush reiterated an “outperform” rating and set a $21.00 target price (down previously from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $23.33.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.